Publication Type:
Periodical
Source(s):
The Lancet; July-August 2022, Vol. 400 Issue: 10349 p359-368, 10p
Abstract:
We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1–2 inhibitor, for the treatment of patients admitted to hospital with COVID-19.
